Indomethacin stimulates activity and expression of ecto-5′-nucleotidase/CD73 in glioma cell lines

European Journal of Pharmacology

Volumn 569, Issue 1-2, 2007, Pages 8-15

  Bernardi, Andressa ^a   Bavaresco, Luci ^a   Wink, Márcia R ^a   Jacques Silva, Maria C ^a   Delgado Cañedo, Andrés ^b   Lenz, Guido ^a   Battastini, Ana M O ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Instituto de Cardiologia de Porto Alegre   (Brazil)

Author keywords

Adenosine; Ecto 5 nucleotidase CD73; Glioma; Indomethacin

Indexed keywords

5' NUCLEOTIDASE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE A3 RECEPTOR; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; INDOMETACIN; MESSENGER RNA; PURINE NUCLEOTIDE;

ARTICLE; CATALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GLIOMA CELL; HUMAN; HUMAN CELL; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

5'-NUCLEOTIDASE; ACTINS; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CELL PROLIFERATION; DIMETHYL SULFOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLIOMA; HUMANS; INDOMETHACIN; QUINAZOLINES; RECEPTORS, PURINERGIC P1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THEOPHYLLINE; TIME FACTORS; TRIAZOLES; XANTHINES;

EID: 34547450732     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.04.058     Document Type: Article

References (39)

1. Abbracchio M.P. P1 and P2 receptors in cell growth and differentiation. Drug Dev. Res. 38 (1996) 393-406
2. Baek J.S., Wilson C.L., Lee C.H., and Eling E.T. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. Pharmacol. Exp. Ther. 301 (2002) 1126-1131
3. Bajaj S.L., Insel J., Quagliata F., Hirschhorn R., and Silber R. Adenosine and adenosine analogues are more toxic to chronic lymphocytic leukemia than to normal lymphocytes. Blood 62 (1983) 75-80
4. Bernardi A., Jacques-Silva M.C., Delgado-Cañedo A., Lenz G., and Battastini A.M.O. Nonsteroidal anti-inflammatory drugs inhibit the growth of C6 and U138-MG glioma cell lines. Eur. J. Pharmacol. 532 (2006) 214-222
5. Bigner S.H., Mark J., Burger P.C., Mahaley M.S., Bullard D.E., Muhlabir L.H., and Bigner D.D. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 48 (1988) 405-411
6. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 218-541
7. Brambilla R., Cattabeni F., Ceruti S., Barbieri D., Franceschi C., Kim Y.C., Jacobson K.A., Klotz K.N., Lohse M.J., and Abbrachio M.P. Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. Naunyn-Schmiedeberg's Arch. Pharmacol. 361 (2000) 225-234
8. Chan K., Delfert D., and Junger K.D. A direct colorimetric assay for Ca2+-ATPase activity. Anal. Biochem. 157 (1996) 375-380
9. Courade J.P., Besse D., Delchambre C., Hanoun N., Hamon M., Eschalier A., Caussade F., and Cloared A. Acetaminophen distribution in the rat central nervous system. Life Sci. 69 (2001) 1455-1464
10. Eli Y., Przedeeki F., Levin G., Kariv N., and Raz A. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem. Pharmacology 61 (2001) 565-571
11. Fishman P., Bar-Yehuda S., and Wagman L. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth: possible explanation for the rarity metastases in muscle. Cancer Res. 58 (1998) 3181-3187
12. Fredholm B.B., Abbracchio M.P., Burnstock G., Dubyak G.R., Harden T.K., Jacobson K.A., Schwabe U., and Williams M. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol. Sci. 18 (1997) 79-82
13. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., Kelloff G.J., Hill D.L., and Seibert K. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60 (2000) 5599-5602
14. Han S., and Roman J. COX-2 inhibitors suppress integrin alpha-5 expression in human lung carcinoma cells through activation of ERK: involvement of Sp1 and AP-1 sites. Int. J. Cancer 116 (2005) 536-546
15. Hansen K.R., Resta R., Webb C.F., and Thompson L.F. Isolation and chacarterization of the promoter of the human 5′-nucleotidase 9CD730-encoding gene. Gene 167 (1995) 307-312
16. Hunter M., and Karin M. The regulation of transcription by phosphorilation. Cell 70 (1992) 375-387
17. Jacobson K.A., Hoffmann C., cattabeni F., and Abbracchio P. Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis 4 (1999) 197-311
18. Lemmens R., Vanduffel L., Teuchy H., and Culic O. Regulation of proliferation of LLC-MK2 cells by nucleosides and nucleotides: the role of ecto-enzymes. J. Biochem. 316 (1996) 551-557
19. Merighi S., Varani K., Geni S., Cattabriga E., Lannotta V., Ulouglu C., Leung E., and Borea P.A. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br. J. Pharmacol. 34 (2002) 1215-1226
20. Merighi S., Mirandola P., Varini K., Gessi S., Leung E., Baraldi P.G., Tabrizi M.A., and Borea P.A. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol. Ther. 1 (2003) 31-48
21. Morrone F.B., Jacques-Silva M.C., Horn A.P., Bernardi A., Schwartsmann G., Rodnight R., and Lenz G. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. J. Neuro-oncol. 64 (2003) 211-218
22. Morrone F.B., Oliveira D.L., Gamermann P., Stella J., Wofchuk S., Wink M.R., Meurer L., Edelweinss M.I.A., Lenz G., and Battastini A.M.O. In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer 6 (2006) 226
23. Navarro J.M., Olmo N., Turnay J., López-Conejo M.T., and Lizarbe M.A. Ecto-5′-nucleotidase from a human colon adenocarcionoma cell line: correlation between enzyme activity and levels in intact cells. Mol. Cell. Biochem. 187 (1998) 121-131
24. Node K., Kitakaze M., Minamino T., Tada M., Inoue M., Hori M., and Kamada T. Activation of ecto-5′-nucleotidase by protein kinase C and its role in ischaemic tolerance in the canine heart. Br. J. Pharmacol. 120 (1997) 273-281
25. Ohana G., Bar-Vehuda S., Barer F., and Fishman P. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J. Cell. Physiol. 186 (2001) 19-23
26. Parker S.L., Tong T., Bolden S., and Wingo P.A. Cancer statistics. CA Cancer J. Clin. 47 (1997) 5-27
27. Ralevic V., and Burnstocck G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50 (1998) 413-492
28. Sadej R., Spychala J., and Skladanowski C. Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res. 16 (2006) 213-222
29. Saxena A., Shriml M.L., Dean M., and Ali U.I. Comparative molecular genetic profiles of anaplasic astrocytomas/glioblastomas multiformes and their subsequent recurrences. Oncogene 18 (1999) 1385-1390
30. Schubert T., Ogata, Marchini C., Ferroni S., and Rudolphi K. Protective mechanisms of adenosine in neurons and glial cells. Ann. N.Y. Acad. Sci. 825 (1997) 1-10
31. Spychala J., Zimmermann A.G., and Mitchell B.S. Tissue-specific regulation of the ecto-5′-nucleotidase Promoter. J. Biol. Chem. 274 (1999) 22705-22712
32. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15 (2001) 2057-2072
33. Turnay J., Olmo N., Reence G., Von der Mark K., and Lizarbe M.A. 5′-nucleotidase actrivity in cultured cell lines: effect of different assay conditions and correlation with cell proliferation. In Vitro Cell. Dev. Biol. 25 (1989) 1055-1061
34. Williams C.S., Watson A.J.M., Sheng H., Helou R., Shao J., and DuBois R.N. Cancer Res. 60 (2000) 6045-6051
35. Wink M.R., Lenz G., Braganhol E., Tamajusuku A.S.K., Schwartsmann G., Sarkis J.J.F., and Battastini A.M.O. Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. Cancer Lett. 198 (2003) 211-218
36. Yoshida S., Harada H., Nagai H., Fukito K., Teramoto A., and Emi M. Head-to-head juxtaposition of Faz-associated phosphatase-1 (FAP-1) and c-Jun NH2-terminal Kinase 3 (JNK3) genes: genomic structure and seven polymorphisms of the FAP-1 gene. J. Hum. Genet. (2002) 614-619
37. Zhang J., Zhu Z.G., Ji J., Yuan F., Yu Y.Y., Liu B.Y., and Lin Y.Z. Transcription factor Sp1 expression in gastric cancer and its relationship to long-term prognosis. World J. Gastroenterol. 11 (2005) 2213-2217
38. Zimmermann H. Ectonucleotidases: some recent developments and a note on nomenclature. Drug Dev. Res. 52 (2001) 44-56
39. Zimmermann H. 5′-Nucleotidase: molecular structure and functional aspects. Biochem. J. 285 (2002) 345-354